BioSpace News Archive

Tevard Biosciences, the pioneer of tRNA-based therapies for severe genetic diseases, announced the appointment of leading tRNA scientist Zoya Ignatova, Ph.D, to its scientific advisory board.

The growth opportunities in the dermatological drugs market are growing at a noticeable speed due to numerous factors.

According to Transparency Market Research’s latest report on the global collagen peptide and gelatin market for the historical period 2017–2018 and forecast period 2019–2027, increase in commercialization of novel collagen-based drug delivery systems and rise in social awareness about personal well-being are projected to drive the global collagen peptide and gelatin market

The growth opportunities in the Capsule Endoscopy System Market are growing at a noticeable speed due to numerous factors.

RELIEF THERAPEUTICS Holding SA, a biopharmaceutical company seeking to provide patients therapeutic benefit from serious diseases with high unmet need, announced promising three-month stability data on a new formulation of RLF-100®.

Mainz Biomed N.V., a molecular genetics diagnostic company specializing in the early detection of cancer, announced the appointment of Dr.

Helixmith announced topline results from the double-blind placebo controlled multicenter study for TADIOS involving one hundred subjects infected with COVID-19.

United Therapeutics Corporation, a public benefit corporation, announced its financial results for the quarter ended June 30, 2022.

Boehringer Ingelheim, a leading research-driven biopharmaceutical company, continued to increase its supply of medicine to patients in the first half of 2022, as it expanded its research pipeline in an increasingly challenging economic, political and regulatory environment.

Regeneron Pharmaceuticals, Inc. announced encouraging initial data from an ongoing Phase 1/2 trial investigating REGN5678, a novel PSMAxCD28 costimulatory bispecific antibody, in combination with the company’s PD-1 inhibitor Libtayo® in advanced metastatic castration-resistant prostate cancer.